HGS is a commercially focused biopharmaceutical company with a broad pipeline of novel drugs that includes three promising products in late-stage development – one already commercialized and two moving toward commercialization:

• BENLYSTA™ (belimumab) has successfully completed Phase 3 development in systemic lupus, and we expect the submission of marketing applications in the United States, Europe and other regions in the first half of 2010.
• ZALBIN™ (albinterferon alfa-2b) has successfully completed Phase 3 development in chronic hepatitis C, and we expect the submission of global marketing applications in fourth quarter 2009. 
• In May 2009, we filed a Biologics License Application for raxibacumab with FDA for inhalational anthrax.
  

Strong Partners

Both BENLYSTA and ZALBIN are partnered with world leaders in the pharmaceutical industry – GlaxoSmithKline (GSK) for BENLYSTA and Novartis for ZALBIN. Raxibacumab is being developed under a contract with the U.S. Government and represents a new way to address the threat of inhalational anthrax.

Therapeutic and Commercial Potential

We believe both BENLYSTA and ZALBIN have the therapeutic potential to change and save lives and, assuming regulatory approval, the commercial potential to become leading products in the marketplace.

In April 2009, we completed delivery of 20,000 doses of raxibacumab to the U.S. Strategic National Stockpile for use in the event of an emergency need. In July, we received a new purchase order for an additional 45,000 doses to be delivered over a three-year period, beginning near the end of this year.

Right behind these three late-stage products is a high-potential mid-stage pipeline led by mapatumumab, our HGS-ETR1 TRAIL receptor 1 antibody for cancer – and including a number of products to which HGS has substantial financial rights in the GSK pipeline.

Financial Performance

We are committed to excellence in our financial performance. Our cash position remains strong, with approximately $697 million in cash and investments as of the end of the third quarter of 2009.